| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Neurosciences: NeurologyNeurology Posters |
1 Radiology, Mayo Clinic, Rochester, Minnesota; 2 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania
922
Objectives: C11 PIB PET has been shown to correlate with the presence amyloid in neurodegenerative disease. The short half-life of C11 PIB makes its clinical use problematic. F18-PET amyloid ligands would be preferable. Brain amyloid imaging with F18 AV-138 was evaluated.
Methods: Four normal control (MMSE median 29.5) subjects (NC) and mild to moderate 5 Alzheimer’s Disease (MMSE median 22, range 14-24) subjects (AD) were imaged with 18F AV-138 PET. Subjects received 5 mCi, (mean 4.6, range 3.0-5.5) of 18F AV-138 and thereafter dynamic brain PET imaging for 3 hrs was performed. Regional brain accumulation was evaluated with Logan plot analysis over 90 minutes to obtain a DVR and a 40-60 minute frame set was used to obtain a delay phase uptake ratio (DUR). Cortical ROIs were normalized to cerebellum. PET image volumes were co-registered the individuals' MRI scans. MRI scans were spatially normalized to the MNI template by which regions were defined. Global DVR and DUR ratios were calculated using a summation of pre-frontal, orbito-frontal, parietal, temporal, anterior cingulate, and posterior cingulate regional activity. Results from normal and AD subjects were compared.
Results: DVR:DUR mean global values were 1.15:1.17 and 1.50:1.49 for NC and AD subjects respectively which showed good separation of the groups (p=0.030 for DVR and p=0.056 for DUR). Bland Altman plot comparing the DVR and DUR methods suggested good correlation.The DUR for 11C PIB and 18F AV-138 in single AD patient was 2.23 and 1.53 respectively, and was 1.10 and 1.11 in a single NC subject.
Conclusions: 18F AV-138 PET is able to distinguish NC from AD subjects.
Research Support: Avid Radiopharmaceuticals, Inc.
| ||||||||||||||||||||||||||||||||||||||
